Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 13901 - 13925 of 14784 in total
Investigational
Investigational
NY-ESO-1 peptide vaccine is an investigational cancer immunotherapy. It contains a peptide derived from the cancer-testis antigen (NY-ESO-1).
Investigational
M-701 is a recombinant anti-EpCAM/CD3 bispecific antibody.
Investigational
Investigational
Investigational
Luveltamab tazevibulin, formerly known as STRO-002, is novel homogeneous folate receptor alpha (FolRα) targeting antibody-drug conjugate. It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer).
Investigational
Matched Description: … [A257414] It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate …
DCVax-L is a personalized immunotherapy comprising an autologous vaccine with dendritic cells loaded in vitro with autologous tumour lysate.
Investigational
Investigational
Investigational
GC5107 is an investigational intravenous immunoglobulin. It is marketed as IVIG-SN.
Investigational
Investigational
ARO-ANG3 is a subcutaneously administered RNA interference (RNAi)-based investigational medicine targeting angiopoietin-like protein 3 (ANGPTL3). It was granted an orphan drug designation for the treatment of homozygous familial hypercholesterolemia (HoFH).
Investigational
Matched Description: … It was granted an orphan drug designation for the treatment of homozygous familial hypercholesterolemia …
Investigational
EGT-101 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the human sulfamidase (SGSH) transgene. Developed by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type A.
Investigational
Matched Description: … EGT-101 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of
EGT-201 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the alpha-N-acetyglucosaminidase (NAGLU) transgene. Developed by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type B.
Investigational
Matched Description: … EGT-201 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of
Investigational
Investigational
Investigational
PRX-OTC is an intracellular enzyme replacement therapy designed to replace missing or defective enzyme in patients with ornithine transcarbamylase deficiency.
Investigational
ARCT-810 is an mRNA replacement therapy that delivers ornithine transcarbamylase mRNA to hepatocytes.
Investigational
HMI-102 is an investigational gene therapy designed to encode the phenylalanine-4-hydroxylase (PAH) gene, mutated in people with phenylketonuria.
Investigational
ATX-F8-117 is an investigational peptide derived from Factor VIII. Developed by Apitope, it is being investigated for the treatment of hemophilia A.
Investigational
Matched Description: … Developed by Apitope, it is being investigated for the treatment of hemophilia A.[L46163] …
Investigational
MBP-091 is a monoclonal antibody being investigated for the treatment of Marburg virus disease (MVD) caused by infection with Marburg virus (MARV).
Investigational
Matched Description: … MBP-091 is a monoclonal antibody being investigated for the treatment of Marburg virus disease (MVD) …
Displaying drugs 13901 - 13925 of 14784 in total